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ABSTRACT 
 Following its evoked release, DA signaling is 
rapidly terminated by presynaptic reuptake, 
mediated by the cocaine-sensitive DAT. DAT 
surface availability is dynamically regulated by 
endocytic trafficking, and direct PKC activation 
acutely diminishes DAT surface expression by 
accelerating DAT internalization. Previous cell line 
studies demonstrated that PKC-stimulated DAT 
endocytosis requires both Ack1 inactivation, which 
releases a DAT-specific endocytic brake, and the 
neuronal GTPase, Rit2, which binds DAT. 
However, it is unknown whether Rit2 is required 
for PKC-stimulated DAT endocytosis in DAergic 
terminals, or whether there are region- and/or sex-
dependent differences in PKC-stimulated DAT 
trafficking. Moreover, the mechanisms by which 
Rit2 controls PKC-stimulated DAT endocytosis are 
unknown. Here, we directly examined these 
important questions. Ex vivo studies revealed that 
PKC activation acutely decreased DAT surface 
expression selectively in ventral, but not dorsal, 
striatum. AAV-mediated, conditional Rit2 
knockdown in DAergic neurons impacted baseline 
DAT surface:intracellular distribution in DAergic 
terminals from female ventral, but not dorsal, 
striatum. Further, Rit2 was required for PKC-
stimulated DAT internalization in both male and 
female ventral striatum. FRET and surface 
pulldown studies in cell lines revealed that PKC 
activation drives DAT-Rit2 surface dissociation, 
and that the DAT N-terminus is required for both 
PKC-mediated DAT-Rit2 dissociation and DAT 
internalization. Finally, we found that Rit2 and 
Ack1 independently converge on DAT to facilitate 
PKC-stimulated DAT endocytosis. Together, our 
data provide greater insight into mechanisms that 
mediate PKC-regulated DAT internalization, and 
reveal unexpected region-specific differences in 
PKC-stimulated DAT trafficking in bona fide 
DAergic terminals. 
_______________________________________  
 DA neurotransmission is required for motor 
control, learning, memory, motivation, and reward 
(1,2). DAergic dysregulation is evidenced in 
numerous neuropsychiatric disorders, including 
ADHD, ASD, schizophrenia, bipolar disorder, 
addiction, and PD (3-8). DA signaling is tightly 
controlled by the presynaptic DAT, which rapidly 
clears synaptically released DA. DAT is also the 
primary target for addictive and therapeutic 
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psychostimulants, including AMPH, cocaine, and 
methylphenidate (Ritalin), which inhibit DAT as 
competitive substrates (AMPH) and antagonists 
(cocaine and methylphenidate) (9). Genetic DAT 
deletions in mice and Drosophila melanogaster 
elevate extracellular DA concentrations and evoke 
hyperactivity (10-12), and human DAT missense 
mutations have been reported in PD, ADHD and 
ASD patients (13-19). Together, these studies 
underscore that DAT is critical to maintain DAergic 
homeostasis (9).  
 Given its central role in DAergic signaling, 
intrinsic neuronal mechanisms that alter DAT 
surface expression and function are likely to 
significantly impact DAergic transmission.  DAT 
surface availability is dynamically modulated by 
endocytic trafficking (20-22). A negative 
regulatory mechanism, or “endocytic brake”, 
tempers basal DAT endocytosis (23,24), and acute 
PKC activation disengages the DAT endocytic 
brake, stimulates DAT internalization, and rapidly 
diminishes DAT surface expression (25,26). The 
DAT N- and C-termini encode residues required to 
engage the DAT endocytic brake, and, when 
mutated, markedly accelerate DAT internalization 
(15,23,27). We previously reported that the non-
receptor tyrosine kinase, Ack1 (AKA: TNK2), is a 
critical component of the DAT endocytic brake, and 
that Ack1 inactivation is required for PKC-
mediated brake release (24).  
 Rit2 (AKA: Rin) is a neuronal small GTPase 
that lacks a CAAX domain, and associates with the 
plasma membrane in a phosphoinositide-dependent 
manner (28-30). Rit2 gene expression is highly 
enriched in DA neurons (31), and several recent 
GWAS studies identified Rit2 SNPs and long 
tandem repeat variants associated with multiple 
DA-related disorders, including PD, ASD, and 
schizophrenia (32-37). However, despite its disease 
association, relatively little is known about 
endogenous DAergic Rit2 function. We previously 
reported that DAT directly binds to Rit2, and that 
Rit2 activity is required for PKC-stimulated DAT 
internalization (38). Moreover, we recently found 
that in vivo DAergic Rit2 knockdown (Rit2-KD) 
differentially alters acute cocaine sensitivity in 
males and females (39).  However, it remains 
unknown whether PKC-stimulated DAT 
internalization in DAergic terminals requires Rit2, 
and whether there are region- or sex-specific 
differences in DAT’s reliance upon Rit2. Further, it 
is unclear how intrinsic DAT domains influence the 
DAT-Rit2 interaction, or whether Rit2 and Ack1 
coordinate to release the DAT endocytic brake. In 
the present study, we leveraged biochemical and 
genetic approaches, in both cultured cells and ex 
vivo mouse striatal slices, to directly address these 
salient questions.  
RESULTS 
 
Rit2 cellular expression and antibody specificity 
 In our previous study, in which we initially 
reported the DAT-Rit2 (Rin) interaction (38), there 
were several paradoxical findings regarding 1) how 
PKC activation impacted the DAT-Rit2 interaction, 
and 2) the Rit2 expression profile across various 
cell lines. In cellular imaging studies, which used 
CFP-Rit2, Rit2 appeared to remain at the plasma 
membrane following PKC-stimulated DAT 
internalization, suggesting that PKC may drive 
DAT and Rit2 to dissociate. In contrast, parallel co-
IP studies found that PKC activation increased the 
DAT-Rit2 interaction in PC12 cells. Furthermore, 
although Rit2 expression is reportedly restricted to 
neurons (28,29,31,40), we detected a single, 
~20kDa immunoreactive band by immunoblot in all 
neuronal and non-neuronal cell lines tested, as well 
as Rit2 mRNA expression in these cell lines by 
standard RT-PCR. The previous studies utilized the 
anti-Rit2 monoclonal antibody, clone 27G2, and in 
that report we additionally confirmed that 27G2 
specifically recognizes Rit2, but not Rit1, (the 
ubiquitously expressed Rit2 homologue) using 
fluorescently-tagged Rit2 and Rit1 fusion proteins. 
Recently, we decided to take advantage of highly-
specific, Rit2-directed, real-time qPCR probes to 
re-assess the Rit2 expression profile across a large 
panel of human, mouse and rat cell lines, as well as 
in mouse and rat midbrain, all of which exhibit the 
single, 20kDa immunoreactive band when probed 
with the anti-Rit2 27G2. To our surprise, Rit2 
mRNA was undetectable in any of the mouse or rat 
cell lines tested, whereas a robust Rit2 mRNA 
signal was detected in both mouse and rat midbrain 
controls (Table I). Moreover, among the human cell 
lines tested, Rit2 mRNA was only detected in SK-
N-DZ cells, as previously reported (40), and at low 
levels in SH-SY5Y cells. However, SK-N-MC and 
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HEK293T cells expressed markedly less/negligible 
Rit2 signal than SK-N-DZ cells, ranging from 20-
300-fold less (Table I). 
Our current RT-qPCR results raised the possibility 
that although 27G2 recognizes Rit2, it also may 
cross-react with a ubiquitously expressed protein 
that has an electrophoretic mobility close to that of 
Rit2. To test this, we screened several newer, 
commercially available anti-Rit2 antibodies using 
cell lysates from HEK293T cells transfected with 
CFP-Rit2. Consistent with our previous report, 
clone 27G2 identified a single 20kDa band in both 
transfected and non-transfected cells, and also 
detected CFP-Rit2 selectively in transfected cells 
(Fig. 1A). However, when immunoblots were 
probed with aRit2 clone 4B5, the low molecular 
weight immunoreactive band was not detected, 
while CFP-Rit2 was detected in transfected cells 
(Fig. 1A). These results are consistent with our RT-
qPCR results and confirm that 27G2 detects an 
artifactual band with an electrophoretic mobility 
close to the Rit2 predicted size. We next used 4B5 
to assess Rit2 in cells transfected with HA-Rit2, and 
in mouse DAergic tissues. Clone 4B5 detected a 
single, ~28kDa immunoreactive band selectively in 
cells transfected with HA-Rit2, which was identical 
in mobility to an immunoreactive band detected 
with aHA, in parallel (Fig. 1B). aHA also detected 
a higher molecular weight band (~30kDa) 
specifically in cells transfected with HA-Rit2, 
which we did not detect using 4B5 (Fig. 1B), 
suggesting that Rit2 may have multiple isoforms, 
and that 4B5 may only detect one of these.  4B5 also 
detected bands at ~24kDa in mouse lysates 
enriched for either dorsal striatum or ventral 
midbrain (Fig. 1B). These immunoblot results were 
consistent with our RT-qPCR results, and 
confirmed that most cell lines either do not express 
Rit2, or express Rit2 at negligible levels. They 
further support that the 27G2 antibody cannot 
reliably distinguish between Rit2 and a robust, 
artifactual, background band. It should also be 
noted that while 4B5 specifically detects Rit2, it 
does so with extremely low sensitivity, even when 
Rit2 is highly overexpressed. Indeed, using the 4B5 
antibody, we could only detect Rit2 by immunoblot 
in lysates from mouse tissues when a very high 
protein mass was loaded. Moreover, although both 
hRit2 and mRit2 are predicted to have identical 
number of amino acids, and a predicted mass of 
~24kDa each, the overexpressed hRit2 protein ran 
slightly higher than the putative mRit2 band. There 
are two known hRit2 isoforms, variants 1 and 2, 
which are predicted to be ~24kDa and ~17kDa, 
respectively, and our hRit2 cDNA codes for variant 
#1. To date it is unknown whether there are tissue 
specific Rit2 isoforms in mouse neurons. Given that 
there is no global Rit2-/- mouse available, we 
therefore cannot say with absolute certainty that the 
single immunoreactive band in mouse tissue is 
definitively Rit2, or possibly a smaller splice 
variant. Therefore, for the majority of our cell line 
studies, we opted to use HA-Rit2 for greater 
sensitivity in cell lines and did not further assess 
Rit2 protein in tissue. 
Rit2 is required for PKC-stimulated, but not basal, 
DAT internalization 
 In our original DAT-Rit2 study (38), we used 
shRNA to silence Rit2 in SK-N-MC cells and to test 
whether Rit2 is required for PKC-stimulated DAT 
downregulation. In light of our current findings that 
SK-N-MC cells do not appreciably express Rit2, we 
were prompted to 1) re-screen Rit2 targeted 
shRNAs, and 2) reassess whether Rit2 is required 
for PKC-stimulated DAT internalization in SK-N-
DZ cells, which endogenously express Rit2. We 
screened several candidate human Rit2-directed 
shRNAs, and identified two shRNAs (shRit2-104 
and -107) that significantly silenced CFP-hRit2 
protein expressed in Neuro2a cells (Fig. 2A). 
Additionally, both shRit2-104 and -107 
significantly silenced endogenous Rit2 mRNA 
expression in SK-N-DZ cells (Fig. 2B).  We utilized 
shRit2-107 to ask whether Rit2 is required PKC-
stimulated DAT internalization in SK-N-DZ cells. 
Rit2-KD significantly blocked PKC-stimulated 
DAT endocytosis as compared to vector-transduced 
cells (Fig. 2C), consistent with a requisite role for 
Rit2 in PKC-stimulated DAT internalization. The 
ability of shRit2-107 to block PKC-stimulated 
DAT endocytosis was not likely due to off-target 
effects, as shRit2-107 did not decrease expression 
of Rit1, the closest homolog to Rit2 (Fig. 2D). To 
further assure that shRit2-107 effects were specific, 
we repeated these studies with shRit2-104. Similar 
to our findings with shRit2-107, Rit2 silencing with 
shRit2-104 significantly blocked PKC-stimulated 
DAT internalization (Fig. 2E). 
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Rit2 is required for striatal steady state DAT 
surface expression and PKC-stimulated DAT 
internalization in a region- and sex-specific 
manner 
 PKC-stimulated DAT internalization in 
response to phorbol ester treatment has been 
reported by numerous laboratories, in a variety of 
transfected cell lines (15,25,41-45). Moreover, we 
previously reported that phorbol ester (PMA) 
treatment decreases DAT surface levels in DAergic 
terminals in ex vivo total striatal slices containing 
both dorsal (DS) and ventral (VS) striatum (26). 
However, it is unknown whether PKC-stimulated 
DAT internalization differs between DAergic 
terminal regions, such as DS and VS, or between 
males and females. Moreover, although Rit2 is 
required for PKC-stimulated DAT internalization 
in SK-N-DZ cells (Fig. 2), it is unknown whether 
Rit2 is required for PKC-stimulated DAT 
endocytosis in DAergic terminals. We recently 
leveraged the TET-OFF system to achieve 
conditional, inducible DAergic Rit2-KD in 
Pitx3IRES2-tTA mice, in which AAV9-shRit2 injection 
into mouse VTA significantly silenced Rit2 
expression in both VTA and SNc (39). We found 
that DAergic Rit2 silencing decreased total striatal 
DAT protein in males, but not females. Further, 
although total DAT protein decreased within male 
total striatum, the DAT surface:intracellular ratio 
was unchanged in either DS or VS, resulting in less 
overall surface DAT in both male striatal 
subregions (39). In the current study, we extended 
our in vivo Rit2-KD studies and asked whether Rit2 
impacts DAT basal distribution in female DS and 
VS. We further asked whether PKC-mediated DAT 
internalization requires Rit2 in male and female DS 
and VS. Male and female Pitx3IRES2-tTA/+ mice VTA 
were bilaterally injected with either AAV9-TRE-
eGFP or AAV9-TRE-shRit2, and DAT surface 
expression was measured by ex vivo slice 
biotinylation in the VS and DS, following treatment 
±1µM PMA, 30 min, 37°C.  
We first examined the effect of Rit2 silencing on 
DAT surface expression in female DS and VS, 
under both basal and PKC-stimulated conditions. 
Surprisingly, in DS, PKC activation did not 
decrease DAT surface expression in control female 
mice (Fig. 3A). Moreover, DAergic Rit2-KD had 
no effect on DS DAT surface expression, under 
either basal or PKC-stimulated conditions (Fig. 
3A). In contrast, in female VS, PKC activation 
significantly reduced DAT surface levels, and 
DAergic Rit2-KD completely blocked further 
surface loss in response to PKC activation (Fig. 
3B).  Moreover, DAergic Rit2-KD significantly 
reduced the basal DAT surface level in female VS, 
as compared to control mice (Fig. 3B). 
Our previous study probed the impact of DAergic 
Rit2 KD on basal DAT surface levels in males (39). 
Therefore, we next asked whether Rit2 was 
required for PKC-stimulated DAT internalization 
in male DS and VS. Similar to females, PKC 
activation had no effect on DAT surface expression 
in DS, but significantly decreased DAT surface 
expression in VS, measured in control (eGFP-
injected) male mice (Fig 4A). Also similar to 
females, DAergic Rit2-KD completely abolished 
PKC-stimulated DAT internalization in male VS 
(Fig. 4B). Given that phorbol esters can stimulate a 
variety of signaling pathways in addition to PKC, 
we further tested whether PMA-induced DAT 
internalization in VS was PKC-mediated. Pre-
treatment with the PKC-specific inhibitor BIM I 
(1µM, 15 min, 37°C) significantly abolished PMA-
induced DAT internalization, and treatment with 
BIM I alone was not significantly different from 
BIM I/PMA (Fig. 4C), clearly demonstrating that 
PMA-mediated DAT internalization in DAergic 
terminals is PKC-dependent.    
Releasing the PKC-sensitive DAT endocytic brake 
drives DAT-Rit2 dissociation at the plasma 
membrane 
 We next sought to decipher the molecular 
mechanisms by which Rit2 impacts DAT 
trafficking. We first asked whether driving DAT 
internalization, by disengaging the PKC-sensitive 
DAT endocytic brake, impacts the DAT-Rit2 
interaction at the plasma membrane. To specifically 
interrogate the DAT surface population and its 
associated protein complex, we leveraged a BBS-
targeted surface labeling strategy (46-48) to label 
DAT in intact cells. We engineered a BBS into the 
DAT extracellular loop 2, a site we previously 
successfully targeted for bio-orthogonal DAT 
labeling (49), and which also tolerates an HA 
epitope (50). BBS-DAT expressed and functioned 
comparably to wt-DAT, and PKC activation 
acutely decreased BBS-DAT function to 67.97 
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±5.9% control levels (Fig. 5A), which is 
comparable to PKC-mediated DAT 
downregulation as previously reported by our group 
and others (22,38,43,49,51). We first tested 
whether BBS-DAT could: 1) specifically isolate 
surface DAT via bungarotoxin labeling and 
pulldown, and 2) recover DAT-associated proteins. 
HEK293T cells expressing HA-Rit2 and either 
BBS-DAT or wt-DAT were incubated with a-
BTX-b, and DAT surface complexes were isolated 
from cell lysates by streptavidin pulldown. We 
specifically recovered BBS-DAT, but not wt-DAT, 
following a-BTX-b incubation (Fig. 5B), 
demonstrating the selectivity of the BBS pulldown 
approach to label and isolate surface BBS-DAT. 
Importantly, Rit2 was recovered from pulldowns 
with BBS-DAT, but not in control pulldowns from 
cells expressing wt-DAT, demonstrating that Rit2 
is recovered specifically following surface DAT 
pulldown. Additionally, BBS-DAT pulldowns did 
not recover the Rit2 homolog, Rit1 (Fig. 5C), 
consistent with a specific association between DAT 
and Rit2. We further asked whether other proteins 
required for PKC-mediated brake release are also 
part of the DAT surface complex. We previously 
reported that the non-receptor tyrosine kinase, 
Ack1 (TNK2) imposes the PKC-sensitive 
endocytic brake, and that PKC-mediated Ack1 
inactivation is required for PKC-stimulated DAT 
internalization (24). However, it is not known 
whether Ack1 is associated with DAT at the plasma 
membrane. Following a-BTX-b labeling and 
pulldown, Ack1 was recovered from cells 
expressing BBS-DAT, but not from control cells 
expressing wt-DAT (Fig. 5D), demonstrating that 
Ack1 is part of the DAT surface complex. Thus, 
BBS-DAT has precise utility to interrogate surface 
DAT and its associated proteins, such as Rit2 and 
Ack1. 
 Given our previous cellular imaging results 
(38), we hypothesized that PKC activation causes 
DAT and Rit2 to dissociate. Since PKC-stimulated 
DAT internalization can only occur when the 
endocytic brake is disengaged, we first leveraged 
BBS-DAT pulldowns to ask whether PKC-
mediated brake release alters the DAT-Rit2 surface 
association. PKC activation (1µM PMA, 30 min, 
37°C) significantly decreased the DAT-Rit2 plasma 
membrane association (Fig. 6A). Additionally, 
DAT and Rit2 significantly dissociated when we 
directly released the DAT endocytic brake, by 
inactivating Ack1 with AIM-100 (20µM, 30 min, 
37°C) (Fig. 6B). DAT and Rit2 may specifically 
dissociate at the cell surface in response to releasing 
the PKC-sensitive endocytic brake, or may do so 
following any stimulus that drives DAT 
internalization. To discern between these two 
possibilities, we measured the DAT-Rit2 surface 
association in response to AMPH treatment, which 
also accelerates DAT internalization, but is Rho-
dependent (52). In contrast to PKC-stimulated 
DAT-Rit2 dissociation, AMPH treatment (10µM, 
30 min, 37°C) significantly increased the DAT-Rit2 
surface association (Fig. 6C). Thus, the DAT-Rit2 
surface dissociation occurs specifically when the 
PKC-sensitive DAT endocytic brake is disengaged, 
either in response to PKC activation or direct Ack1 
inactivation, but is not a general result of 
accelerated DAT endocytosis. 
The DAT amino terminus is integral to the DAT-
Rit2 interaction and PKC-stimulated dissociation  
 The DAT-Rit2 interaction was originally 
identified in a yeast 2-hybrid screen, using DAT C-
terminal residues 587-596 (FREKLAYAIA) as bait 
(38). However, it is not known which DAT domains 
are required (or sufficient) for the DAT-Rit2 
association in the context of intact DAT protein, nor 
is it known whether any DAT domains are 
specifically required for PKC-stimulated DAT-Rit2 
dissociation. Rit2 specifically binds DAT, but not 
SERT (38), thus we hypothesized that replacing 
DAT N- or C- termini with those of SERT may 
define DAT domains required for Rit2 binding 
and/or PKC-stimulated DAT-Rit2 dissociation. To 
test this possibility, we leveraged a series of 
DAT/SERT chimeras we previously characterized 
(53), in which either the DAT N-, C-, or both 
termini were substituted with those of SERT. 
HEK293T cells were co-transfected with YFP-Rit2 
and CFP-tagged versions of these chimeras, and we 
performed live FRET imaging to quantify the 
chimera-Rit2 interactions. As we previously 
reported, control CFP-DAT and YFP-Rit2 elicited 
a significant FRET signal as compared to soluble 
YFP/CFP expression (Fig. 7A). Interestingly, 
replacing the DAT N-terminus with that of SERT 
(CFP-N-S/DAT) significantly increased the DAT-
Rit2 interaction compared to CFP-DAT, whereas 
replacing the DAT C-terminus (CFP-DAT/C-S) or 
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both termini (CFP-S/DAT/S) did not affect the 
DAT-Rit2 interaction (Fig. 7A). We also observed 
a significant increase in the interaction between 
YFP-Rit2 and CFP-N-S/DAT using the donor 
recovery after photobleaching approach (Fig. 7B), 
demonstrating that the FRET signal is a bona fide 
interaction between the fluorophores. Using the 
BBS pulldown approach, Rit2 was likewise 
recovered with BBS-tagged versions of each 
DAT/SERT chimera (Fig. 7C). We next asked 
whether PKC-stimulated DAT-Rit2 dissociation 
requires either the DAT N- and/or C-termini. 
Substituting the DAT C-terminus with that of 
SERT (DAT/C-S) had no significant effect on 
PKC-stimulated DAT-Rit2 dissociation, as 
compared to wt-DAT controls (Fig. 7D, one-way 
ANOVA with Dunnett’s multiple comparison test, 
p=0.69). However, substituting the DAT N- 
terminus with that of SERT (N-S/DAT) completely 
abolished PKC-stimulated DAT/Rit2 dissociation, 
and there was a strong trend for attenuated 
DAT/Rit2 dissociation when both DAT N- and C- 
termini were replaced by SERT (S/DAT/S) (Fig 
7D, p=0.058). Taken together, these results indicate 
that the DAT N-terminus is required for the PKC-
stimulated DAT-Rit2 dissociation, and that the 
SERT N-terminus does not suffice. However, 
SERT N- and C- termini suffice to maintain the 
DAT-Rit2 association. 
The DAT amino terminus is required for PKC-
stimulated DAT internalization 
 Since the DAT N-terminus is required for 
PKC-stimulated DAT-Rit2 dissociation, this raised 
the possibility that the N-terminus may also be 
required for stimulated DAT internalization, driven 
by release of the DAT endocytic brake. To test 
these possibilities, we measured DAT and 
DAT/SERT chimera internalization rates in 
response to either PKC activation or direct Ack1 
inactivation (with AIM-100) in stably-transfected 
SK-N-MC cells, in which we previously 
characterized both PKC- and AIM-100-stimulated 
DAT internalization (24,26). PKC activation (1µM 
PMA, 10 min, 37°C) significantly increased wt-
DAT internalization, and substituting the DAT C-
terminus with the SERT C-terminus (DAT/C-S) did 
not significantly affect PKC-stimulated 
internalization (Fig. 8A). However, PKC-
stimulated DAT internalization was abolished 
when either the DAT N-terminus, or both N- and C-
termini, were substituted with SERT termini (N-
S/DAT and S/DAT/S, Fig. 8A). In contrast, direct 
Ack1 inactivation (20µM AIM-100, 10 min, 37°C) 
significantly stimulated wt-DAT, N-S/DAT, and 
DAT/C-S internalization, but had no effect on 
S/DAT/S internalization (Fig. 8A). We further 
evaluated the basal endocytic rates of the chimeric 
DATs, as compared to wt-DAT. As presented in 
Figure 8B, none of the chimera basal internalization 
rates differed significantly from wt-DAT. To assure 
that these effects were not due to the lack of Rit2 
expression in SK-N-MC cells, we further assessed 
basal and PKC-stimulated N-S/DAT internalization 
in stably transfected SK-N-DZ cells, which 
endogenously express Rit2 (Table I). In SK-N-DZ 
cells, N-S/DAT internalized significantly slower 
than wt-DAT under basal conditions (Fig 8C). 
Additionally, while PKC activation significantly 
increased the wt-DAT internalization rate, it had no 
effect on N-S/DAT internalization as compared to 
its own vehicle control (p=0.17, one-way ANOVA 
with Bonferroni’s multiple comparison test, n=4-7). 
These results demonstrate that the DAT N-terminus 
is required, and that the SERT N-terminus does not 
suffice, for PKC-stimulated DAT internalization.  
Rit2 and Ack1 independently converge on DAT in 
response to PKC  
 We next asked whether there is a mechanistic 
relationship between Rit2, Ack1, and PKC-
mediated DAT endocytic brake release. Rit2 may 
be either upstream or downstream from Ack1 in the 
signaling cascade that leads from PKC to DAT. 
Alternatively, Rit2 and Ack1 may respond 
independently to PKC activation to stimulate DAT 
internalization. We first used Rit2-KD in SK-N-DZ 
cells to ask whether Rit2 was required for PKC-
mediated Ack1 inactivation, a requisite step for 
PKC-mediated release of the endocytic brake and 
for stimulated DAT internalization (24). As we 
previously reported, in vector-transduced cells, 
PKC activation significantly reduced pY284-Ack1, 
to levels comparable to that achieved with the Ack1 
inhibitor, AIM-100 (Fig. 9A). In cells transduced 
with shRit2-107, pY284-pAck1 levels, were also 
significantly reduced in response to either PKC 
activation or AIM-100 treatment, and there was no 
difference in the magnitude change of pY284-
pAck1 levels following PKC activation (Fig. 9A). 
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These results indicate that Rit2 is not likely 
upstream of Ack1 in the signaling pathway that 
leads from PKC to Ack1 inactivation.  
 We next asked whether PKC-mediated Ack1 
inactivation is required for, and therefore upstream 
of, PKC-stimulated DAT-Rit2 dissociation. To test 
this possibility, we measured DAT-Rit2 
dissociation in cells co-transfected with DAT, Rit2, 
and either vector or the PKC-insensitive, 
constitutively active Ack1 mutant (S445P) which 
we previously reported blocks PKC-stimulated 
DAT internalization (24). In control cells, PKC 
activation drove a significant DAT-Rit2 
dissociation (Fig. 9B). In cells co-transfected with 
S445P-Ack1, PKC activation likewise drove DAT-
Rit2 dissociation, at levels indistinguishable from 
vector controls (Fig. 9B). These results demonstrate 
that PKC-stimulated DAT-Rit2 dissociation does 
not require Ack1 inactivation. Moreover, they 
demonstrate that even in conditions where DAT 
cannot internalize in response to PKC activation 
(i.e. because Ack1 is constitutively active), PKC 
activation still drives DAT and Rit2 to dissociate. 
Thus, PKC-stimulated DAT-Rit2 dissociation is 
likely to occur prior to Ack1-mediated release of 
the DAT endocytic brake. 
 
DISCUSSION 
 DAT is stabilized at the cell surface by a PKC-
sensitive endocytic brake that requires 1) residues 
in both the DAT N- and C- termini to engage 
(23,27), and 2) Ack1 inactivation to be released 
(24). Here, we found that Rit2 is required to release 
the PKC-sensitive DAT endocytic brake in cell 
lines and tissues where Rit2 is endogenously 
expressed, such as SK-N-DZ cells (Fig. 2C) and in 
VS (Fig. 3 and Fig. 4), respectively. Curiously, over 
two decades of evidence has demonstrated that 
PKC activation stimulates DAT internalization in 
in a wide range of cultured cell lines (42,50,54-56), 
which our results demonstrate have negligible, if 
any, Rit2 expression  (Table 1). Given that Ack1 is 
ubiquitously expressed, and that Rit2 and Ack1 
converge independently on DAT in response to 
PKC activation (Fig. 9), we conclude that PKC-
stimulated Ack1 inactivation can suffice to release 
the endocytic brake when DAT is heterologously 
expressed in a context that does not express Rit2. 
However, when DAT is expressed in its appropriate 
context (i.e. striatal terminals), Rit2 expression is 
absolutely required for PKC-stimulated DAT 
internalization, and PKC-mediated Ack1 
inactivation alone does not suffice to release the 
endocytic brake (Fig. 3 and Fig. 4). These results 
further suggest that although Rit2 and Ack1 
independently converge on DAT in response to 
PKC activation in cell lines (Fig. 9), there may be 
an, as of yet, unidentified DAergic-specific 
mechanism(s) that facilitate a Rit2/Ack1 
interdependence required for endocytic brake 
release.  
 Our previous study using total (i.e. not sub-
dissected) striatal slices found that PKC activation 
decreased DAT surface expression by ~20% (26). 
Interestingly, in the current study, PKC activation 
drove ~35% DAT surface loss in both male and 
female VS, but had no effect on DAT surface 
expression in DS from either sex (Fig. 3). These 
data suggest that the somewhat modest PKC-
stimulated DAT surface loss detected in total 
striatum reflects robust DAT surface loss in VS, 
diluted by the lack of a net effect in DS. Is DAT 
endocytosis completely resistant to PKC activation 
in DS? It is currently unknown which PKC 
isoform(s) stimulate DAT internalization. We 
activated PKC with the phorbol ester PMA, which 
activates all diacylglycerol-sensitive PKC 
isoforms, including PKC-a, b1, b2, g, and d. PKCb 
activity is required for D2 receptor-mediated DAT 
insertion into the plasma membrane, and selective 
PKCb activation rapidly delivers DAT to the cell 
surface in both cell lines and striatal synaptosomes 
(57). Thus, it is possible that in DS, Rit2-dependent, 
PKC-stimulated DAT internalization may be 
countered by PKCb-mediated DAT insertion, 
resulting in no detectable net change within the 30-
min timeframe we tested. In contrast to DS, DAT 
surface levels in VS were significantly decreased in 
response to PMA treatment, suggesting that the 
balance between PKCb-mediated DAT insertion 
and Rit2-dependent DAT internalization may differ 
between DS and VS. A recent study by Blakely and 
colleagues (58) further supports this premise, in 
which they reported that D2R activation increased 
DAT surface expression in the DS, but not VS. 
Given that few studies, to date, have identified the 
receptor-mediated signaling pathways that lead to 
PKC-stimulated DAT internalization, nor the 
temporal profile of DAT response to PKC 
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activation in DAergic terminals, it remains unclear 
how DAT insertion and internalization balance may 
occur. Finally, although our current data indicate 
that Rit2-KD is required for PKC-stimulated DAT 
endocytosis in female and male VS, it is important 
to bear in mind that DAT basal surface expression 
in both male (39) and female (Fig. 3B) VS were 
reduced following DAergic Rit2-KD. Thus, there is 
a possibility that a general floor effect blocked 
PKC-mediated DAT internalization, rather than a 
requirement for Rit2. However, we do not believe 
that this is likely, as DAT is capable of undergoing 
additive degrees of internalization when cells are 
subjected to dual PKC activation and AMPH 
exposure (59). 
 We used an extracellular BBS-tag to 
interrogate surface DAT and its associated protein 
complex. This approach was previously used 
successfully by several groups (46,47,60), and has 
distinct advantages over co-IP approaches, since 1) 
the a-BTX/BBS affinity is significantly higher than 
that of antibody/antigen interactions, and 2) a-
BTX/BBS binding is maintained in detergent 
lysates. Moreover, using an extracellular labeling 
approach, in general, maintains intracellular protein 
complexes that might be disrupted using an 
intracellularly-targeted antibody in 
lysates/solution. Interestingly, although we 
observed significant DAT-Rit2 dissociation in 
response to releasing the PKC-sensitive DAT 
endocytic brake (Fig. 6), AMPH-stimulated DAT 
internalization increased the surface DAT-Rit2 
population. Surface DAT is distributed among 
several membrane microdomains (38,61-67). 
Moreover, we previously reported that, 1) PKC 
activation preferentially depletes DAT from 
cholera toxin-positive (Ctx+) microdomains (26), 
and 2) there is significantly more DAT-Rit2 co-
localization in Ctx+ microdomains (38). 
Conversely, AMPH treatment increases DAT 
localization to Ctx+ domains (63). Taken together, 
these results suggest that DAT may dissociate from 
Rit2, and internalize, preferentially from Ctx+ 
microdomains in response to PKC activation. In 
contrast, AMPH potentially drives DAT 
internalization from Ctx- domains, in which there is 
less DAT-Rit2 interaction, thereby leaving an 
enriched DAT-Rit2 population at the cell surface.  
 We originally identified the DAT-Rit2 
interaction via a yeast 2-hybrid screen using the C-
terminal DAT domain “FREKLAYAIA” as bait, 
and FRET studies revealed that Rit2 directly 
interacts with DAT, but not SERT, at the plasma 
membrane (38). However, the domains required for 
the DAT-Rit2 interaction, and their requirement for 
either PKC-stimulated DAT internalization or 
DAT-Rit2 dissociation were not defined. To 
address these questions, we used a series of 
DAT/SERT chimeras previously reported by our 
lab (53), and found that the DAT N-terminus was 
required for PKC-stimulated DAT-Rit2 
dissociation (Fig. 8). Indeed, under basal 
conditions, N-S/DAT and Rit2 interacted to a 
significantly higher degree than DAT-Rit2 controls 
(Fig. 6), consistent with a lack of DAT-Rit2 
dissociation for the N-S/DAT chimera and higher 
steady-state interaction. N-S/DAT also basally 
internalized significantly slower than wt-DAT 
selectively in SK-N-DZ, consistent with its 
inability to disengage the endocytic brake. 
Moreover, DAT/C-S retained both Rit2 interaction 
and ability release the endocytic brake in response 
to PKC activation. This was surprising, given that 
1) the DAT C-terminal bait (FREKLAYAIA) used 
to identify the DAT/Rit2 interaction is highly 
conserved across the SLC6 gene family (23,44), 
and 2) full-length SERT does not interact with Rit2 
(38).  So, while the FREKLAYAIA domain is 
sufficient to interact with Rit2, its context within 
full-length DAT or SERT appears to dictate 
ultimate Rit2 binding potential. Interestingly, 
although N-S/DAT was resistant to PKC-
stimulated internalization, it retained AIM-100-
dependent internalization, whereas S/DAT/S did 
not (Fig. 8), indicating that the DAT N-terminus is 
not required for direct Ack1-dependent endocytic 
brake release, and further supports the hypothesis 
that Rit2 and Ack1 converge on DAT 
independently in response to PKC activation. It 
should also be noted that we, and others, reported 
that AIM-100 also binds non-competitively to DAT 
(24,68), and recent reports suggest that AIM-100 
can enhance DAT surface oligomerization (68,69). 
Since both Ack1-dependent and AIM-100-
stimulated internalization are specific for DAT, and 
not SERT, it is possible that S/DAT/S endocytic 
resistance to AIM-100 may be because the 
substituted SERT domains perturb the DAT/AIM-
100 interaction. Likewise, it is possible that the 
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ability of N-S/DAT to internalize in response to 
AIM-100, but not PKC activation, may be due to a 
direct AIM-100 effect on DAT. 
 In this study we present one of the first 
descriptions of region- and sex-dependent 
differences in DAT trafficking regulation. 
Furthermore, we greatly extend our knowledge of 
the mechanisms by which Rit2 governs DAT 
surface expression in bona fide DAergic terminals. 
Future studies that examine the cell autonomous 
endogenous signaling events that drive striatal DAT 
trafficking, and require Rit2, will shed further light 
on mechanisms that influence DA clearance and 
DA-dependent behaviors. 
EXPERIMENTAL PROCEDURES 
Materials 
Phorbol 12-myristate 13-acetate (PMA) was from 
LC Laboratories (P-1680). GF 109203X 
(Bisindoylmaleimide I, BIM I) and AIM-100 were 
from Tocris-Cookson. All other reagents were from 
either Sigma-Aldrich or Fisher Scientific, and were 
of the highest possible grade.  
Animals 
All studies were conducted in accordance with 
UMASS Medical School IACUC Protocol A-1506 
(H.E.M). Pitx3IRES2-tTA mice on the C57Bl/6 
background were the generous gift of Dr. Huaibin 
Cai (National Institute on Aging), and were 
continually backcrossed to C57Bl/6 mice. Mice 
were maintained in 12hr light/dark cycle at constant 
temperature and humidity and food and water were 
available ad libitum. 
Antibodies 
Primary antibodies used: mouse anti-Rit2 18G4 
(27G2; Sigma), mouse anti-Rit2 4B5 (GTX83711, 
GeneTex), rat anti-DAT (MAB369), mouse anti-
SERT (ST51-2; Mab Technologies), rabbit anti-HA 
(C29F4; Cell Signaling Technology), mouse anti-
GFP (Roche), mouse anti-Ack1 (A-11; sc-28336), 
and rabbit anti-pY284-Ack1 (Millipore). 
Horseradish peroxidase-conjugated secondary 
antibodies: goat anti-rat, goat anti-mouse and goat 
anti-rabbit were from Jackson ImmunoResearch. 
Plasmids and cloning 
N-S/DAT (SERT1-78/DAT60-620), DAT/C-S 
(DAT1-583/SERT601-630), and S/DAT/S 
(SERT1-78/DAT60-583/SERT601-630) plasmids, 
in which either the DAT N-terminus (N-S/DAT), 
C-terminus (DAT/C-S), or both termini (S/DAT/S) 
were substituted with those of SERT, were 
generated as previously described (53) using PCR-
ligation-PCR approach to clone the DAT or SERT 
terminal domains onto the hSERT or hDAT-
pCDNA3.1(+) backbone. CFP-tagged chimeras 
were generated by cloning their cDNAs into the 
pECFP-C1 vector using HindIII/XbaI (N-S/DAT), 
HindIII (DAT/C-S), and HindIII/SalI (S/DAT/S). 
Bungarotoxin binding site (BBS)-tagged hDAT and 
DAT chimera constructs were generated using the 
extracellular tagging strategy as previously 
described (49) with the following amino acid 
sequence inserted into extracellular loop 2 of hDAT 
and DAT chimera constructs: 
GSSGSSGWRYYESSLEPYPDGSSGSSG. The 
underlined BBS is flanked by linker sequences. All 
plasmids were verified by Sanger sequencing 
(Genewiz). Human constitutively active Ack1 
mutant (S445P-Ack1-HA) was generated as 
previously described (24).  
AAV production and stereotaxic viral delivery 
pscAAV-TRE-eGFP and pscAAV-TREmiR33-
shRit2-eGFP plasmids were generated as 
previously described (39), and AAV particles 
(AAV9 serotype) were produced, purified, and 
titers determined by the University of 
Massachusetts Medical School Viral Vector Core, 
as previously described (70). For intracranial 
stereotaxic AAV injections, male and female mice 
(minimum 3 weeks age) were anesthetized with 
100mg/kg ketamine/10mg/kg xylazine (I.P.), and 
20% mannitol was administered (I.P.) 15 minutes 
prior to viral delivery, to increase viral spread (71). 
Mouse heads were shaved, placed in the stereotaxic 
frame, and bilateral 0.8mm holes were drilled into 
the skull at the indicated stereotaxic coordinates. 
1µl of the indicated viruses were infused bilaterally 
into the VTA (Bregma: anterior/posterior: -
3.08mm, medial/lateral: ±0.5mm, dorsal/ventral: -
4.5mm) at a rate of 0.2µL/min. Syringes were left 
in place for a minimum of 5 minutes post-infusion 
prior to removal. Mice were housed for a minimum 
of four weeks before experiments were performed. 
Viral expression in each animal was confirmed by 
visualizing GFP expression in 0.3mm coronal 
ventral midbrain slices.  
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Ex vivo slice biotinylation 
Ex vivo striatal slices were prepared 4-5 weeks 
following viral injection in Pitx3IRES2-tTA/+ mice (for 
Rit2 KD studies), or from 5-7 week old C57Bl/6J 
(for PKC specificity studies). Mice were sacrificed 
by cervical dislocation and rapid decapitation and 
heads were immediately submerged in ice cold, 
oxygenated cutting solution, pH 7.4 (in mM: 20 
HEPES, 2.5 KCl, 1.25, NaH2PO4, 30 NaHCO3, 25 
glucose, 0.5 CaCl2·4H2O, 10 MgSO4·7H2O, 92 N-
methyl-D-glucamine (NMDG), 2.0 thiourea, 5.0 
Na+-ascorbate, 3.0 Na+-pyruvate) for 1 min. Brains 
were removed and 300µm coronal slices were 
prepared with a VT1200 Vibroslicer (Leica) in ice-
cold, oxygenated cutting solution. Slices were 
hemisected along the midline, and were recovered 
in ACSF, pH 7.4 (in mM: 125 NaCl, 2.5 KCl, 1.24, 
NaH2PO4, 26 NaHCO3, 11 glucose, 2.4 
CaCl2·4H2O, and 1.2 MgCl2·6H2O) 40 min, 31°C. 
Hemi-slices were treated ±1µM PMA in ACSF, 
30min, 37°C with constant oxygenation, using their 
contralateral hemi-slice as a vehicle-treated control. 
Following drug treatment, slices were moved to ice 
and surface DAT was labeled by biotinylation as 
previously described (24,26,39). Briefly, slices 
were biotinylated with membrane-impermeant 
sulfo-NHS-SS-biotin (1mg/ml), 45min, 4°C. 
Residual biotin was quenched 2x 20 min washes of 
ice-cold ACSF supplemented with 100mM glycine, 
and were washed with ice-cold ACSF. Hemi-slices 
were enriched for dorsal and ventral striatum, by 
sub-dissecting in a line from the anterior 
commissure to the lateral olfactory tract. Sub-
dissected slices were lysed in RIPA buffer 
containing protease inhibitors, and tissue was 
disrupted by triturating sequentially through a 
200µL pipet tip, 22G and 26G tech-tips. Samples 
rotated 30min at 4°C to complete lysis, insoluble 
material was removed by centrifugation, and 
protein concentrations were determined using the 
BCA protein assay. Biotinylated proteins were 
isolated by batch streptavidin chromatography, 
overnight with rotation, 4°C, at a ratio of 20µg 
striatal lysate to 30µL streptavidin agarose beads, 
which was empirically determined to recover all 
biotinylated DAT. Recovered proteins were 
washed with RIPA buffer and eluted from beads in 
2X SDS-PAGE sample buffer, 30min, room 
temperature with rotation. Eluted (surface) proteins 
and their respective lysate inputs were resolved by 
SDS-PAGE, and DAT was detected by 
immunoblotting as described above. %DAT at the 
cell surface was calculated by normalizing surface 
signals to the corresponding total DAT input signal 
in a given hemi-slice, detected in parallel. Note that 
all slice data for Rit2-KD experiments in the current 
study were acquired during the course of our 
previous study, in which we first achieved AAV-
mediated Rit2 KD (39). Basal DAT surface levels 
in vehicle-treated male slices were compared and 
reported in that study, and thus were not re-
analyzed for the current study. However, the DAT 
surface levels from vehicle-treated male hemislices 
were re-used in the current study as controls to 
determine whether PMA treatment affected DAT 
surface levels in contralateral hemi-slices. Rit2 
knockdown in females was confirmed by RT-qPCR 
(Fig. S1c of previous study (39)). For males, 
successful viral expression (AAV9-eGFP and 
AAV9-eGFP-shRit2) was confirmed by visual 
detection of GFP reporter immunofluorescence in 
midbrain slices from each experimental animal. For 
PKC specificity studies, data were reported as 
%change in DAT surface levels in drug-treated 
hemislices, normalized to their vehicle-treated, 
contralateral hemi-slices.  
Cell Culture and transfection 
Cells were maintained at 37°C, 5% CO2. SK-N-
MC cells were grown in MEM (Sigma), and 
HEK293T, HEK293 (FRET studies) and N2a cells 
were grown in DMEM (CellGro/Corning), each 
supplemented with 10% fetal bovine serum, 2mM 
glutamine, and 100 units/mL penicillin-
streptomycin. SK-N-DZ cells were grown in 
DMEM (ATCC #30-2002) supplemented with 
10%FBS, 1X non-essential amino acids (Gibco) 
and 100u/mL penicillin-streptomycin. HEK293T 
cells were transfected using Lipofectamine 2000 
(Invitrogen) according to manufacturer’s 
instructions with the following modifications: For 
biochemical and RT-qPCR studies, cells were 
seeded into 6-well plates at a density of 1x106 (SK-
N-MC), 5x105 (HEK293T), or 2.5x105 (N2a) 
cells/well one day prior to transfection, and were 
transfected with 3μg (SK-N-MC) or 2μg 
(HEK293T and N2a) plasmid DNA/well using a 
lipid:DNA ratio of 2:1 (SK-N-MC and HEK293T) 
or 4:1 (N2a). Stable cell lines were generated by 
selecting cells starting 48 hrs following 
transfection, with 0.5 mg/mL (SK-N-MC) or 0.8 
 at U
niversity of M
assachusetts M
edical Center/The Lam
ar Soutter Library on A
pril 13, 2020
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 11 
mg/L (SK-N-DZ) G418 (Geneticin, Invitrogen/Life 
Technologies). Stably transfected cells were pooled 
and cell lines were maintained under selective 
pressure using 0.2 mg/mL or 0.32 mg/mL G418 for 
SK-N-MC and SK-N-DZ cells, respectively. For 
FRET imaging studies, HEK293 cells were seeded 
into an 8-well chambered coverslip (ibidi) at a 
density of 2x104 cells/well one day prior to 
transfection, and were transfected with the 
indicated plasmids using JetPRIME (Polyplus-
transfection) according to the manufacturer’s 
protocol. FRET studies were performed 24 hrs post-
transfection. 
shRNA, Lentiviral production and cell 
transduction 
GIPZ lentiviral shRNA constructs targeted to Rit2, 
and empty pGIPZ vector control, were obtained 
from Dharmacon. Tested shRNA clone ID’s and 
mature antisense sequences were as follows: 
shRit2-104: V3LHS_380104; 
CTTCTTCTTCAAAGAACCT 
shRit2-105: V3LHS_380105; 
TTGTTACCCACCAGCACCA 
shRit2-107: V3LHS_380107; 
CTTCTTCTTCAAAGAACCT 
Lentiviral particles were produced in HEK293T 
cells as previously described (24). For cell 
transduction, 1x106 cells DAT-SK-N-DZ cells were 
seeded onto 6-well plates and were transduced with 
3.0mL of lentiviral supernatant, supplemented with 
0.8µg/mL polybrene, 16-24 hours post-seeding. 
Cells were selected for transduction beginning 24 
hours post-infection (72 hrs total) with SK-N-DZ 
media supplemented with 1.25µg/mL puromycin. 
Assays were conducted 96 hrs post-transduction.  
FRET 
FRET was measured using an iMIC inverted 
microscope (TILL Photonics GmbH). Samples 
were focused using a 60X (N.A. 1.49) oil objective 
(Olympus). Fluorescence was excited using a 100 
W Xenon Lamp (Polychrome, Till Photonics 
GmbH). Excitation light was filtered through either 
a 436/20 nm (CFP) or 514/10 nm (YFP) excitation 
filter (Semrock) and directed to the sample via a 
442/514 dual line dichroic mirror (Semrock). 
Emitted fluorescence light was filtered through a 
480/40 nm - 570/80 nm dual emission filter 
(Semrock) and directed to a beamsplitter unit 
(Dichrotom, Till Photonics). Briefly the emission 
light was separated spatially according to the 
fluorescence wavelength using a 515 nm dichroic 
mirror (Semrock). The resultant two channels 
(<515 nm & >515 nm) were projected next to each 
other onto an EMCCD chip (iXon Ultra 897Andor) 
and recorded using Live Acquisition software 
(version 2.5.0.21; TILL Photonics GmbH). To 
guarantee the best signal to noise ratio and dynamic 
range, the camera was operated in 16-bit mode with 
a readout speed of 1 MHz. According to 
manufactories recommendation; an EM-Gain of 16 
was applied to overcome the noise floor. To analyze 
FRET (see below) two images were taken per set 
(Donor excitation -> Donor Emission / Acceptor 
Emission and Acceptor Excitation -> Acceptor 
Emission respectively). Per condition ten sets were 
recorded each experimental day; the images were 
then analyzed using Offline Analysis software 
(version 2.5.0.2; TILL Photonics GmbH). One 
region of interest (part of the plasma membrane) per 
cell was selected in the CFP channel. Background 
fluorescence was subtracted from each image and 
the average intensity of each region of interest was 
used for calculations. Spectral bleed through (BT) 
for donor (0.57) and acceptor (0.04) was 
determined using HEK293 cells expressing a CFP 
or YFP signal only. Normalized FRET (NFRET) 
was calculated as follows:  NFRET= 𝐼()*+ − (𝐵𝑇01213 × 	𝐼01213) − 	(𝐵𝑇7889:;13 × 	 𝐼7889:;13	)<𝐼01213 × 	𝐼7889:;13 	𝑥	100 
A fused CFP-YFP construct (CYFP) was included 
as positive control, resulting in maximum FRET. 
Non-fused donor and acceptor fluorophores were 
included as a negative control. To confirm that the 
calculated NFRET values reflect bona fide 
FRET, donor (CFP) recovery after acceptor 
(YFP) photobleaching (DRAP) experiments were 
included to support the conclusion that 
the fluorophore-tagged proteins directly interact at 
the site of the photobleaching. Average acceptor 
photobleaching was 85±4% (mean ±SD). 
 
RNA extraction & RT-qPCR 
RNA was isolated from cell lines and rodent 
midbrain using RNAqueous®-Micro Kit RNA 
Isolation (Thermo Fisher Scientific). For ventral 
 at U
niversity of M
assachusetts M
edical Center/The Lam
ar Soutter Library on A
pril 13, 2020
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 12 
midbrain samples, 1.0 mm bilateral tissue punches, 
encompassing both the ventral tegmental area and 
substantia nigra par compacta, were taken from 
300µm acute mouse and rat midbrain slices. 
Reverse transcription was performed using 
RETROscript® Reverse Transcription Kit (Thermo 
Fisher Scientific). Quantitative PCR was performed 
and analyzed using the Applied Biosystems® 7500 
Real-Time PCR System Machine and Software, 
using Taqman® Gene Expression Assays for 
human Rit2 (Hs01046673_m1), Rit1 
(Hs00608424_m1), and GAPDH 
(Hs99999905_m1), mouse Rit2 
(Mm01702749_mH), and GAPDH 
(Mm99999915_g1), and rat Rit2 
(Rn01760884_m1) and GAPDH 
(Rn01775763_g1).  
[3H]DA uptake assay 
SK-N-MC cells stably expressing BBS-DAT were 
seeded onto 96-well plates at a density of 
7.5x104/well 24 hrs prior to assay. Cells were 
washed twice with Krebs-Ringer-HEPES buffer 
(120mM NaCl, 4.7mM KCl, 2.2mM CaCl2, 1.2mM 
MgSO4, 1.2mM KH2PO4, and 10mM HEPES, pH 
7.4) and pre-incubated in KRH supplemented with 
0.18% glucose ±1µM PMA, 30 min, 37°C. 100nM 
desipramine was included in all samples to 
eliminate uptake contribution of endogenous 
norepinephrine transporter. DA uptake was 
initiated by addition of 1µM [3H]DA (Perkin 
Elmer: Dihydroxyphenylethylamine (Dopamine), 
3,4-[Ring-2,5,6-3H]) in KRH supplemented with 
0.18% glucose, 10µM pargyline, and 10µM 
ascorbic acid. Assays proceeded for 10min, 37°C, 
and were terminated by three rapid washes with ice-
cold KRH buffer. Cells were solubilized in 
scintillation fluid, and accumulated radioactivity 
was determined by liquid scintillation counting in a 
Wallac MicroBeta scintillation plate counter. Non-
specific DA uptake was defined in the presence of 
10μM GBR12909.  
Internalization Assays and Immunoblotting 
 Relative internalization rates over 10 minutes were 
measured by reversible biotinylation as previously 
described (24,25,44). Briefly, the indicated stably 
transfected cells were seeded into 6-well plates at 
1.5x106 cells/well one day prior to analysis. Cells 
incubated twice with 2.5 mg/mL sulfo-NHS-SS-
biotin (15 min, 4°C) and quenched twice with 
PBS2+ (PBS, pH 7.4, 1.0mM MgCl2, 0.1mM CaCl2) 
supplemented with 100mM glycine (15 min, 4°C). 
Internalization was initiated by rapidly warming 
cells in prewarmed PBS2+ supplemented with 
0.18% glucose, 0.2% protease-/IgG-free bovine 
serum albumin, and proceeded for 10min, 37°C in 
the presence of the indicated drugs. Parallel 
surface-labeled controls remained at 4°C. Cells 
were rapidly cooled by washing thrice with ice-cold 
NT buffer (150mM NaCl, 20mM Tris, pH 8.6, 
1.0mM EDTA, pH 8.0, 0.2% protease-/IgG-free 
bovine serum albumin) and remaining surface 
biotin was stripped by reducing in 100mM TCEP in 
NT buffer twice (25 min, 4°C). Cells were rinsed 
rapidly in PBS2+, and were lysed in RIPA buffer 
(10mM Tris, pH 7.4, 150mM NaCl, 1.0mM EDTA, 
0.1% SDS, 1% Triton-X-100, 1% sodium 
deoxycholate) containing protease inhibitors 
(1.0mM PMSF and 1.0g/mL each leupeptin, 
aprotinin, and pepstatin). Lysates were cleared by 
centrifugation and protein concentrations were 
determined with the BCA protein assay (Thermo 
Fisher) using BSA as a standard. Biotinylated 
proteins were recovered by streptavidin batch 
chromatography from equivalent amounts of cell 
lysate, and were eluted in 2X Laemmli sample 
buffer, 30 min, room temperature with rotation. 
Eluted proteins were resolved by SDS-PAGE and 
proteins were detected and quantified by 
immunoblotting: hDAT and DAT/C-S were 
detected with amino-directed rat anti-DAT 
(MAB369, Millipore, 1:2000), and N-S/DAT and 
S/DAT/S were detected with amino-directed mouse 
anti-hSERT (MAb Technologies,1:2000). 
Immunoreactive bands were detected using a 
VersaDoc imaging station (Bio-Rad), and were in 
the linear range of detection. Internalization rates 
were calculated as %surface protein internalized/10 
min, as compared to their respective surface signal 
at t=0 min (controls that were biotinylated and kept 
at 4°C). Note that for all representative 
immunoblots shown throughout the study, all 
brightness/contrast manipulations were made 
uniformly across any given blot. For presentation 
purposes, immunoreactive bands were cropped 
from the same exposure of the same immunoblot.  
BBS-DAT/chimera pulldowns 
HEK293T cells were transiently co-transfected 
with HA-Rit2, and either BBS-DAT or BBS-DAT 
chimeras, at a DAT:Rit2 plasmid ratio of 1:4, as 
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described above. Cells were washed thrice with ice 
cold PBS2+ and surface BBS-DAT chimeras were 
labeled with 120μM biotinylated α-bungarotoxin 
(α-BTX-b, Thermo Fisher) in PBS2+, 2 hrs, 4ºC. For 
drug treatments, cells were treated with the 
indicated drugs 30 min, 37°C, prior to labeling with 
α-BTX-b. Following labeling, α-BTX-b solution 
was removed, cells were washed thrice with ice 
cold PBS2+, and were lysed in ice-cold co-
immunoprecipitation (co-IP) lysis buffer (50mM 
Tris, pH 7.4, 100mM NaCl, 1% Triton X-100, 10% 
glycerol, and 1.0mM EDTA) containing protease 
inhibitors (1.0mM PMSF and 1.0g/mL each 
leupeptin, aprotinin, and pepstatin) and 
Phosphatase Inhibitor Cocktail V (EMD Millipore), 
30 min, 4°C. Labeled proteins were recovered from 
equivalent amounts of protein by batch affinity 
chromatography with streptavidin-coupled M280 
Dynabeads (Thermo Fisher), 4°C, overnight with 
rotation. Lysate/bead ratios were empirically 
determined to assure quantitative recovery of all 
labeled proteins in lysates. Beads were gently 
washed thrice with ice-cold co-IP buffer, with 
magnetic recovery between washes, and isolated 
proteins were eluted from beads in an equal volume 
of co-IP lysis buffer and 2X SDS-PAGE sample 
buffer (100mM Tris, pH 6.8, 4.4% SDS, glycerol, 
100mM DTT, and 0.04% bromophenol-blue). 
Isolated proteins were resolved by SDS-PAGE, and 
specific protein bands were detected by 
immunoblotting with antibodies for rat anti-DAT 
(1:2000), mouse anti-hSERT (1:2000), and rabbit 
anti-HA (1:2000) as indicated above. 
Immunoreactive HA-Rit2 band densities were 
normalized to their respective recovered DAT, or 
chimera, bands in each independent experiment.  
Statistical Analysis 
All data were analyzed using GraphPad Prism 
software. Prior to analyses, statistical outliers 
within data sets were identified using either 
Grubb’s or Rout’s outlier test, and were removed 
from further analysis. Specific statistical tests used 
are detailed within each figure legend. For 
comparisons between two groups, a Student’s t test 
was used. For comparison among more than two 
experimental groups, one-way ANOVA with 
appropriate post-hoc multiple comparison test was 
performed, as indicated within each figure legend. 
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Table I. Rit2 expression in mammalian cell lines and rodent brain regions 
Rit2 mRNA expression was determined by RT-qPCR and normalized to 
internal GAPDH values. n = 2-4 
 
Species/Cell line Rit2 (2-DCtx104 ±S.E.M) 
  
Mouse 
 
CAD 0.02 ±0.0067  
N2a 0.09 ±0.052 
NIH/3T3 No signal detected 
Midbrain 72.0 ±12.8 
Cortex 54.8 ±9.19 
Rat  
AN27 No signal detected 
PC12 No signal detected 
Midbrain 110.0 ±0.51 
Human 
 
HEK293T 0.40 ±0.34 
SH-SY5Y 1.3 ± 0.56  
SK-N-MC 0.09 ±0.07  
SK-N-DZ 27.2 ±18.7 
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Figure 1. Rit2 protein is specifically detected by clone 4B5, but not clone 27G2, aRit2 antibodies. Rit2 
detection in transfected cell lines and mouse tissues by immunoblot. A. HEK293T cells were transfected 
with either vector (-) or CFP-Rit2 (+) and cell lysates were assessed by immunoblot 48 hrs. post-
transfection, probing with either aRit2 clones 27G2 (left) or 4B5 (right) as described in Materials and 
Methods. Molecular weight markers indicate kDa. B. HEK293T cells transfected with vector (-) or HA-
Rit2 (+), mouse ventral midbrain (vMB), and striatum (Str), were assessed by immunoblot, probing with 
either aHA (left) or aRit2 clone 4B5 (right). 10µg/lane and 100µg/lane were loaded for transfected cell 
lysates and mouse brain lysates, respectively. Arrowheads indicate Rit2 immunoreactive bands. 
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Figure 2. Rit2 is required for PKC-stimulated DAT internalization in DAT-SK-N-DZ cells. A. Human 
Rit2 shRNA screen. Mouse N2a cells were co-transfected with human CFP-Rit2, and either pGIPZ vector, 
luciferase293 control, or the indicated Rit2 shRNA-pGIPZ plasmids. Top: Representative immunoblots. 
Bottom: Average CFP-Rit2 levels, normalized to actin loading controls, expressed as %pGIPZ vector 
±S.E.M. Asterisks indicate a significant difference from pGIPZ controls Asterisks indicate a significant 
difference from pGIPZ controls (one-way ANOVA F(4, 14) = 6.396, p = 0.004; Dunnett’s multiple 
comparisons test, pGIPZ vs. shRit2-104: **p = 0.005; vs. shRit2-105: p = 0.36; vs shRit2-107: **p = 0.006; 
vs luc693: p = 0.95, n=3-5). B. shRit2-mediated knockdown in stable DAT-SK-N-DZ cells. DAT-SK-N-DZ 
cells were transduced with control, shRit2-104, or shRit2-107 lentiviral particles, and Rit2 mRNA 
expression was measured by RT-qPCR 96 hrs post-transduction. Average   Ct values are presented, 
expressed as %control-transduced values ±S.E.M. Asterisks indicate a significant difference from pGIPZ 
controls (one-way ANOVA F(2, 16) = 25.09, p<0.0001; Dunnett’s multiple comparisons test: pGIPZ vs 
shRit2-104: ***p = 0.0001; vs shRit2-107: ****p<0.0001, n=4-9). C. DAT internalization assay. Stable 
DAT-SK-N-DZ cells were transduced with the indicated lentiviral particles and DAT internalization rates 
were measured 96 hrs post-transduction as described in Materials and Methods. Top: Representative 
immunoblots depicting surface DAT expression at t=0 (T), strip control (S), and internalized DAT during 
either vehicle (V) or 1 µM PMA (P) treatment. Bottom: Average DAT internalization rates expressed as 
%vehicle-treated control rates ±S.E.M. *p=0.04, one-tailed Student’s t test, n=6-8. D. Rit1 mRNA 
expression specificity control. DAT-SK-N-DZ cells were transduced with control, or shRit2-107 lentiviral 
particles, and Rit1 expression was measured by RT-qPCR 96 hrs post-transduction. Average DDCt values 
are presented, expressed as %control-transduced values ±S.E.M. shRit2-107 transduction did not 
significantly affect Rit1 mRNA expression, p=0.965, two-tailed Student’s t test, n=3. E. DAT 
internalization assays. Stable DAT-SK-N-DZ cells were transduced with the indicated lentiviral particles 
and DAT internalization rates were measured 96 hrs post-transduction as described in Materials and 
Methods. Data are presented identically as in (C).  *p=0.03, one-tailed Student’s t test, n=5.  
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Figure 3. PKC-induced DAT internalization in females is limited to ventral striatum and requires 
Rit2.  Conditional Rit2 silencing in DA neurons and ex vivo striatal slice biotinylation. Female Pitx3IRES2-
tTA/+ mouse VTA were bilaterally injected with either AAV9-TRE-eGFP or -shRit2. Brains were harvested 
4-5 weeks post-injection, and DAT surface expression was measured in ex vivo striatal slices by surface 
biotinylation as described in Materials and Methods, following treatment ±1µM PMA, 30 min, 37°C. 
Representative blots are shown in the top of each panel, and average data are presented at the bottom of 
each panel. DAT surface levels are expressed as %total DAT, ±S.E.M, n=5-8 slices from n=3 independent 
mice/virus. A. Dorsal striatum. Neither PKC activation nor Rit2-KD had an effect on DAT surface 
expression (two-way ANOVA: Interaction: F(1, 22) = 0.051, p = 0.82; drug: F(1, 22) = 0.58, p = 0.46; virus: F(1, 
22) = 0.18, p = 0.68). B. Ventral striatum. PKC activation and Rit2-KD significantly decreased DAT surface 
expression, and Rit2-KD blocked PKC-stimulated DAT internalization (two-way ANOVA: Interaction: F(1, 
18) = 4.54, p = 0.047; drug: F(1, 18) = 4.25, p = 0.054; virus: F(1, 18) = 7.28, p = 0.015. Sidak’s multiple 
comparisons test: eGFP(veh) vs eGFP(PMA): *p = 0.04; eGFP(veh) vs shRit2(veh): *p = 0.02; shRit2(veh) 
vs shRit2(PMA): p > 0.99). 
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Figure 4. PKC-induced DAT internalization in males is limited to ventral striatum and requires Rit2.  
Conditional Rit2 silencing in DA neurons and ex vivo striatal slice biotinylation. Male Pitx3IRES2-tTA/+ mouse 
VTA were bilaterally injected with either AAV9-TRE-eGFP or -shRit2. Brains were harvested 4-5 weeks 
post-injection, and DAT surface expression was measured in ex vivo striatal slices by surface biotinylation 
as described in Materials and Methods, following treatment ±1µM PMA, 30 min, 37°C. Representative 
blots are shown in the top of each panel, and average data are presented at the bottom of each panel. A. 
Effect of PKC activation on DAT surface levels in dorsal vs. ventral striatum. DAT surface levels were 
measured in AAV9-TRE-eGFP-injected mice and are expressed as %total DAT ±S.E.M. PKC activation 
had no effect on DAT surface expression in dorsal striatum, but significantly decreased DAT surface levels 
in ventral striatum (two-way ANOVA: Interaction: F(1, 18) = 1.96, p = 0.18; region: F(1, 18) = 7.76, p = 0.01; 
drug: F(1, 18) = 5.30, p = 0.03. Sidak’s multiple comparisons test (vehicle vs. PMA): Dorsal: p = 0.76; 
Ventral: p = 0.043 n = 5-6 slices from 3 independent mice. B. Rit2-KD significantly blocked PKC-
stimulated DAT internalization in ventral striatum (shRit2: p = 0.86, two-tailed Student’s t test, n=6 slices 
from 3 independent mice). C. PMA-induced DAT internalization is PKC-mediated. DAT surface expression 
was measured in ex vivo VS slices prepared from C57Bl/6J  mice and were pretreated ±1µM BIM I, 15 
min, 37°C prior to PMA treatment as described above. DAT surface levels are expressed as %vehicle 
±S.E.M. BIM I pre-treatment significantly abolished PMA-mediated DAT surface loss (one-way ANOVA 
F(2, 6) = 8.08, p = 0.02; Sidak’s multiple comparisons test, PMA vs BIM/PMA: *p = 0.01, BIM/PMA vs 
BIM: p = 0.25, n = 3 independent mice per condition).  
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Figure 5. Surface DAT associates with Rit2 and Ack1, but not Rit1. A. [3H]DA uptake assay. SK-N-
MC cells expressing BBS-DAT were treated ±1µM PMA, 30 min, 37°C and [3H]DA uptake was measured 
as described in Materials and Methods. Average data are expressed as %vehicle-treated specific [3H]DA 
uptake ±S.E.M. **p=0.009, two-tailed Student’s t test, n=3. B-D. BBS-DAT pulldowns. HEK293T cells 
were co-transfected with DAT (±BBS tag), and either HA-Rit2 (B), GFP-Rit1 (C), or Ack1-HA (D) and 
DAT surface complexes were labeled and isolated by streptavidin pulldown as described in Materials and 
Methods. Representative immunoblots for pull-downs (left panels) and their respective inputs (1/4 total 
input, right panels) are presented (n=3 independent experiments). 
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Figure 6. PKC-mediated endocytic brake release drives DAT-Rit2 dissociation at the plasma 
membrane. BBS-DAT pull-downs. HEK293T cells were co-transfected with BBS-DAT and HA-Rit2, were 
treated ±the indicated drugs, 30 min, 37°C, labeled with a-BTX-b, and DAT surface complexes were 
isolated as described in Materials and Methods. Top panels: Representative immunoblots. Bottom panels: 
Average DAT-Rit2 association expressed as %vehicle-treated control ±S.E.M., assessed by two-tailed 
Student’s t test. A. PKC activation significantly decreased the DAT-Rit2 surface association, *p=0.04, n=6. 
B. Ack1 inactivation with AIM-100 decreased the DAT-Rit2 surface association, *p=0.03, n=4. C. AMPH 
treatment significantly increased DAT-Rit2 surface association, ***p=0.0002, n=3. 
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Figure 7. The SERT N-terminus promotes the DAT-Rit2 interaction and blocks PKC-stimulated 
DAT-Rit2 dissociation. A, B. FRET studies. HEK293 cells were transfected with the indicated plasmids 
and surface FRET measurements were made 24 hrs. post-transfection, as described in Materials and 
Methods.  Average NFRET values (x100) for the indicated pairs are presented as violin plots, with median 
lines provided within each violin. N values are provided for each violin. A. NFRET values. Asterisks 
indicate significant differences between the indicated pairs (Kruskal-Wallis test, p<0.0001 with Dunn’s 
multiple comparisons test: DAT vs N-S/DAT: ****p < 0.0001; vs DAT/C-S: p = 0.13; vs S/DAT/S: p > 
0.99; vs CFP/YFP: ****p < 0.0001.  B. DRAP values. one-way ANOVA F(3, 46) = 3.31, p = 0.028; Dunnett’s 
multiple comparisons test: DAT vs N-S/DAT: *p = 0.02; DAT/C-S: p = 0.81; vs S/DAT/S: p = 0.99.)  C, 
D.  BBS-DAT pull-downs. HEK293T cells were co-transfected with HA-Rit2 and the indicated BBS-tagged 
proteins. Cells were treated ±1µM PMA, 30 min, 37°C, surface-labeled with a-BTX-b and DAT surface 
complexes were recovered by streptavidin pulldown as described in Materials and Methods. C. 
Representative immunoblots. D. Average data presented as %vehicle-treated DAT-Rit2 association for 
each indicated protein. N-S/DAT significantly blocked PKC-stimulated DAT-Rit2 dissociation (one-way 
ANOVA F(3, 28) = 3.44, p = 0.03; Dunnett’s multiple comparisons test: DAT vs N-S/DAT: *p = 0.03; vs 
DAT/C-S: p = 0.69; vs S/DAT/S: p = 0.06, n=5-11).  
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Figure 8. The DAT N-terminus is required for PKC-stimulated internalization. DAT Internalization 
assays. Wt-DAT and DAT/SERT chimera internalization rates were measured ±1µM PMA or ±20µM 
AIM-100, 10 min, 37°C, as described in Materials and Methods. Tops: Representative immunoblots 
showing total surface expression at t=0 (T), strip control (S), and internalized protein during either vehicle 
(V), PMA (P), or AIM-100 (A) treatments. Bottoms: Averaged data. A. Stimulated internalization in stable 
SK-N-MC cell lines. Rates are expressed as %vehicle-treated controls ±S.E.M. Asterisks indicate a 
significant difference from vehicle controls (one-way ANOVA with Dunnett’s multiple comparisons test, 
n=8-13. DAT: ANOVA F(2, 34) = 7.94, p = 0.0015; veh vs PMA: **p = 0.007; veh vs AIM-100: **p = 0.002. 
N-S/DAT: ANOVA F(2, 21) = 4.38, p = 0.03; veh vs PMA: p = 0.82; veh vs AIM-100: *p = 0.02. DAT/C-
S: ANOVA F(2, 30) = 5.22, p = 0.01; veh vs PMA: *p = 0.01; veh vs AIM-100: **p = 0.026. S/DAT/S: 
ANOVA F(2, 21) = 0.84, p  = 0.44. B. Basal internalization in stable SK-N-MC cell lines. Chimera basal 
internalization rates did not significantly differ from wt-DAT (one-way ANOVA F(3, 39) = 4.046, p = 0.013; 
Dunnett’s multiple comparisons test: DAT vs: N-S/DAT: p = 0.54; vs DAT/C-S: p = 0.06; vs S/DAT/S: p 
= 0.72, n=9-12). C. DAT and N/S-DAT internalization in stable SK-N-DZ cell lines. Average internalization 
rates are expressed as %surface protein internalized/10 min, ±S.E.M. Asterisks indicate a significant 
difference from the indicated protein or treatment (two-way ANOVA: interaction: F(1, 16) = 1.06, p = 0.32; 
construct: F(1, 16) = 15.6, p = 0.001; drug: F(1, 16) = 25.6, p = 0.0001; Tukey’s multiple comparisons test: 
DAT(veh) vs DAT(PMA): *p = 0.01, DAT(veh) vs N-S/DAT(veh): *p = 0.03; N-S/DAT(veh) vs N-
S/DAT(PMA): p = 0.21, n=4-7). 
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Figure 9. Rit2 and Ack1 independently converge on DAT downstream of PKC activation. A. Effect of 
Rit2 silencing on PKC-mediated Ack1 inactivation. SK-N-DZ cells were transduced with lentiviral particles 
expressing either vector (pGIPZ) or shRit2-107, and were treated ±1µM PMA or ±20µM AIM-100, 10 min, 
37°C. pY284Ack1 and total Ack1 levels were measured from parallel lysate aliquots by immunoblot. Top: 
Representative immunoblots. Bottom: Average pY284-Ack1 levels expressed as %vehicle-treated control 
cells ±S.E.M. Asterisks indicate a significant difference from vehicle-treated controls (one-way ANOVA 
with Dunnett’s multiple comparisons test, vector: ANOVA F(2, 12) = 16.43, p = 0.0004; veh vs PMA: **p 
= 0.001; vs AIM-100: ***p = 0.0004; shRit2-107: ANOVA F(2, 9) = 5.858, p = 0.02; veh vs PMA: *p = 
0.03; vs AIM-100: *p = 0.03, n=4-5). B. PKC-stimulated DAT-Rit2 dissociation. HEK293T cells were 
triple-transfected with BBS-DAT, HA-Rit2, and either empty vector or S445P-Ack1-HA. Cells were treated 
±1µM PMA, 30 min, 37°C, labeled with a-BTX-b, and DAT complexes were recovered by streptavidin 
pulldown as described in Materials and Methods. Top: Representative immunoblots. Bottom: Average 
DAT-Rit2 association expressed as %vehicle-treated control ±S.E.M. p=0.99, two-tailed Student’s t test, 
n=4.	
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